HeraMED Ltd. (DE:1I4)
FRANKFURT:1I4
Want to see DE:1I4 full AI Analyst Report?
1I4 Stock Chart & Stats
€0.02
<€0.01(10.00%)
At close: 4:00 PM EST
€0.02
<€0.01(10.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.06
Previous CloseN/A
Volume0.00
Average Volume (3M)152.85K
Market Cap
€27.75M
Enterprise Value€21.94M
Total Cash (Recent Filing)€914.65K
Total Debt (Recent Filing)€282.39K
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,157,486,600
10 Day Avg. Volume114,978
30 Day Avg. Volume152,848
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)27.61
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginGross margin rising to ~60% represents a durable improvement in unit economics versus prior years. Higher gross profitability creates room to invest in sales and product, and if sustained can enable operating leverage as revenues scale, improving long-term sustainability.
Deleveraged Balance SheetZero reported debt and positive equity reduce financial risk and interest obligations, giving management flexibility to fund operations or restructure financing. Although the capital cushion is small, the absence of leverage is a durable strength in stress scenarios and for future capital raises.
Niche Digital Women's Health FocusA focused connected-care offering for pregnancy and maternal health targets structural demand (telehealth, remote monitoring). Specialized software and data capture can create sticky clinical integrations and defensible network effects, supporting recurring revenue potential over time.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the business consumes cash to operate, creating ongoing funding needs. Over months, this raises liquidity and dilution risk, constrains reinvestment in growth, and forces reliance on external capital to sustain operations.
Ongoing Operating LossesSustained operating losses indicate the company has not converted improved gross margins into operating profitability. Persistent negative margins erode equity returns, limit retained earnings, and imply continued dependency on financing until structural cost or revenue changes close the gap.
Revenue Volatility And Recent DeclineVolatile and contracting revenue undermines the ability to realize scale benefits from higher gross margins. A shrinking top line increases sensitivity to fixed costs, complicates forecasting and investment decisions, and signals challenges in sustainable customer acquisition or retention.
HeraMED Ltd. News
1I4 FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest stock price was €0.01 and its highest was €0.06 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is €27.75M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 90 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Feb 26, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,157,486,600 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in DE:1I4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:1I4 Sentiment 62%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €35.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
―
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-417.72%
Trailing 12-Months
Asset Growth
-68.43%
Trailing 12-Months
Company Description
HeraMED Ltd.
HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus' heartbeat; and HeraCARE, a digital pregnancy monitor platform for the creation and implementation of digital health solutions for maternity care management. It also develops EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is headquartered in Netanya, Israel.
Technical Analysis
Options Prices
Currently, No data available
---